Mucosal heterologous Prime Boost vaccination generates systemic immunity and protects against a human protozoan parasite.

SANCHEZ ALVERTI A; BIVONA A; CERNY N; TRINITARIO S; CARDOSO, ALEJANDRO C.; GONZALES G; MORALES C; SCHULZE, K; WEIßMANN, S; EBENSEN, T; CAZORLA,S; GUZMAN C; MALCHIODI E

Congreso; IV International Congress in Translational Medicine; 2018

T. cruzi is an obligatory intracellular parasite recognized by WHO as a neglectedtropical disease, which affects 7 million people worldwide, mostly in Latin America. After 100 years of its discovery, there are still no effective vaccines to prevent or treat In this work we employed rational design of the immunogen based in the three dimensional structure, in order to present a multivalent display of key parasitic cytotoxic T lymphocyte (CTL) and antibody targets as well as to omit known immune evasion associated sequences.In search for novel components to increase the levels of CTL response, we have employed cyclic di nucleotides ? 3?5?-c-di-AMP (CDA) a STING agonist during DNA-prime + rProtein-boost vaccination protocols by the intranasal route